Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1015 VectivBio funding
BioCentury & Getty Images

Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

Oct 16, 2020 | 12:54 AM GMT

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that

Read the full 460 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE